Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
The 7 Most Hated Stocks by Institutional Traders
01:03pm, Wednesday, 20'th Sep 2023
While many retail investors are keen to discover which securities the big market players are snapping up, sometimes it's more telling to zero in on the stocks institutional traders are selling. Why? B
Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?
12:47pm, Friday, 08'th Sep 2023
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers
03:39am, Thursday, 07'th Sep 2023
Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially approved drugs for various diseases. Ionis has a str
Ionis to present at upcoming investor conferences
07:05am, Wednesday, 30'th Aug 2023
CARLSBAD, Calif. , Aug. 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
01:00pm, Thursday, 10'th Aug 2023
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates.
Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)
11:31am, Thursday, 10'th Aug 2023
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall St
Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say
10:42am, Wednesday, 09'th Aug 2023
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall St
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
09:58am, Wednesday, 09'th Aug 2023
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. This compares to loss of $0.74 per share a year ago
Ionis to hold second quarter 2023 financial results webcast
07:05am, Wednesday, 26'th Jul 2023
Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study
11:03am, Tuesday, 11'th Jul 2023
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Ionis to present at upcoming investor conference
07:05am, Wednesday, 05'th Jul 2023
CARLSBAD, Calif. , July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
01:39pm, Friday, 02'nd Jun 2023
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Ionis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?
12:39pm, Friday, 02'nd Jun 2023
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 09'th May 2023
CARLSBAD, Calif. , May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: RBC
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
10:41am, Thursday, 04'th May 2023
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates.
